Purple Biotech Statistics

Total Valuation

Purple Biotech has a market cap or net worth of $6.29 million. The enterprise value is -$2.24 million.

Market Cap	6.29M
Enterprise Value	-2.24M

Important Dates

The next estimated earnings date is Friday, May 23, 2025, before market open.

Earnings Date	May 23, 2025
Ex-Dividend Date	n/a

Share Statistics

Purple Biotech has 529.64 million shares outstanding. The number of shares has increased by 48.17% in one year.

Current Share Class	n/a
Shares Outstanding	529.64M
Shares Change (YoY)	+48.17%
Shares Change (QoQ)	+18.40%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	532.01M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.19
P/TBV Ratio	1.25
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.23, with a Debt / Equity ratio of 0.01.

Current Ratio	2.23
Quick Ratio	2.14
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -21.66% and return on invested capital (ROIC) is -19.93%.

Return on Equity (ROE)	-21.66%
Return on Assets (ROA)	-16.60%
Return on Invested Capital (ROIC)	-19.93%
Return on Capital Employed (ROCE)	-32.69%
Revenue Per Employee	n/a
Profits Per Employee	-$804,444
Employee Count	9
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -78.58% in the last 52 weeks. The beta is -0.16, so Purple Biotech's price volatility has been lower than the market average.

Beta (5Y)	-0.16
52-Week Price Change	-78.58%
50-Day Moving Average	2.61
200-Day Moving Average	4.34
Relative Strength Index (RSI)	37.29
Average Volume (20 Days)	287,568

Short Selling Information

Short Interest	65,579
Short Previous Month	49,227
Short % of Shares Out	2.54%
Short % of Float	n/a
Short Ratio (days to cover)	0.27

Income Statement

Revenue	n/a
Gross Profit	-62,000
Operating Income	-10.80M
Pretax Income	18.76M
Net Income	-7.24M
EBITDA	-10.77M
EBIT	-10.80M
Earnings Per Share (EPS)	-$0.02

Full Income Statement

Balance Sheet

The company has $8.52 million in cash and $183,000 in debt, giving a net cash position of $8.34 million or $0.02 per share.

Cash & Cash Equivalents	8.52M
Total Debt	183,000
Net Cash	8.34M
Net Cash Per Share	$0.02
Equity (Book Value)	32.91M
Book Value Per Share	0.06
Working Capital	4.92M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-14.37M
Capital Expenditures	n/a
Free Cash Flow	-14.37M
FCF Per Share	-$0.03

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Purple Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-48.17%
Shareholder Yield	-48.17%
Earnings Yield	-115.19%
FCF Yield	-228.59%

Analyst Forecast

The average price target for Purple Biotech is $33.00, which is 1,366.67% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$33.00
Price Target Difference	1,366.67%
Analyst Consensus	Strong Buy
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 17, 2024. It was a reverse split with a ratio of 0.05:1.

Last Split Date	Sep 17, 2024
Split Type	Reverse
Split Ratio	0.05:1

Scores

Altman Z-Score	n/a
Piotroski F-Score	1